We are live on ! Find out more
SWTX

SpringWorks Therapeutics

Delisted

SWTX was delisted on the 30th of June, 2025.

144 hedge funds and large institutions have $2.82B invested in SpringWorks Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 61 increasing their positions, 43 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 43

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

1% more funds holding

Funds holding: 142144 (+2)

0.53% more ownership

Funds ownership: 91.76%92.29% (+0.53%)

2% less capital invested

Capital invested by funds: $2.86B → $2.82B (-$43.4M)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $2.7M

Holders
144
Holders Change
+2
Holders Change %
+1.41%
% of All Funds
2.21%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
19
Increased
61
Reduced
43
Closed
16
Calls
Puts
$2.7M
Net Calls
-$2.7M
Net Calls Change
-$2.77M

SWTX Hedge Fund Activity: Q4 2021 in Review

144 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2021, worth a combined $2.82B — down 1.5% from $2.86B a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new SWTX positions and 16 closed out — a net gain of 3 holders — while 61 added to existing stakes and 43 trimmed.

The largest buyer was Marshall Wace, adding an estimated $25.6M. The largest seller was Jennison Associates, exiting entirely with an estimated $41M sold.

  • 144 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2021, up from 142 in Q3 2021.
  • Funds reported $2.82B of SpringWorks Therapeutics stock for Q4 2021, down 1.5% quarter-over-quarter.
  • 19 funds opened new SpringWorks Therapeutics positions in Q4 2021 and 16 closed out, a net change of +3 holders.
  • The largest SpringWorks Therapeutics buyer in Q4 2021 was Marshall Wace, an estimated $25.6M added.
  • The largest SpringWorks Therapeutics seller in Q4 2021 was Jennison Associates, an estimated $41M sold.

Based on aggregated 13F filings for Q4 2021.